HISTORICAL AND MODERN ASPECTS OF CYSTIC FIBROSIS IN RUSSIA

The article is dedicated to historical and modern trials in the sphere of mucoviscidosis in Russia, peculiarities of clinical manifestations, pathophysiological and pathomorphological disorders and of the disease course with the analysis of the first results of the register of patients in the Moscow region. The aggregate result of this evaluation is the survival rate in the Moscow region that has become almost equal to the one in the USA and Europe and is considerably higher than in the other regions of the Russian Federation. Such a result reflects many components of specialized care rendered to mucoviscidosis patients in the Moscow region: special centers for children and adults have been founded, patients are actively and regularly checked and may be examined in detail during each visit, while pharmacological support is up to world standards; this is not yet present or is developed insufficiently in many RF subjects. The article also dwells upon the genetic peculiarities of mucoviscidosis important both for diagnosing the disease (including neonatal screening) and creation of a panel for DNA-diagnostics and for determining the disease course to a considerable extent. It also presents information on the prospects of gene therapy development and the first results of clinical studies.

1. Kapranov N. I. Moskva = Moscow. 2012; 163: 12–15.

2. Golubtsova O. I., Kozhevnikova S. L., Krasovskii S. A. Moskva = Moscow. 2012; 165: 143.

3. Accurso F. The Tiger-1 clinical trial on denufosol in cystic fibrosis. Ped. Pumonol. 2008; 31: 191.

4. Debray D., Kelly D., Houwen R., Strandvik B., Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J. Cyst Fibros. 2011 Jun; 10 (2): S29–36. Review.

5. Paediatric protocol for CF related liver disease «Cystic Fibrosis in children and adults» The Leeds Method of Management. St. James’s University Hospital, UK. November 7, 2008. p. 253.

6. Krasovskii S. A., Chernyak A. V., Amelina E. L., Nikonova V. S., Voronkova A. Yu. i dr. Pul'monologiya = Pulmonology. 2012; 3: 61–65.

7. Saiman L., Anstead M., Mayer-Hamblett N. et al. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trail. JAMA. 2010; 303: 1707–1715.

8. Dumo C., Corey M., Zielenski J. et al. Genotype and phenotype correlations in patients with cystic fibrosis and pancreatitis. Gastroenterology. 2002; 123: 1857–1864.

9. Kashirskaya N. Yu., Kapranov N. I. Detskaya gepatologiya: porazhenie pecheni pri mukovistsidoze [Pediatric Hepatology: Liver Disease in Cystic Fibrosis]. Moscow, Dinastiya, 2009, pp. 404–414.

10. Saiman S., Marshall B. C., Meyer-Hamblett N. et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749–1756.

11. Proesmans M., Vermeulen F., De Boeck K. What’s new in cystic fibrosis? From treating symptoms to correction of the basic defect. Eur. J. Pediatr. 2008; 167 (8): 839–849.

12. Van Goor F., Hadida S., Grootenhuis P. D., Burton B., Cao D., Neuberger T., Turnbull A., Singh A. et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA. 2009; 106 (44): 18825–18830.

13. Ramsey B. W., Davies J., McElvaney N. G., Tullis E., Bell S. C., Drevinek P., Griese M., McKone E. F., Wainwright C. E., Konstan M. W. et al CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N. Engl. J. Med. 2011; 365: 1663–1672.

14. Flume P. A., Liou T. G., Borowitz D. S., Li H., Yen K., Ordonez C. L., Geller D. E. Ivacaftor in subjects with cystic fibrosis who are homozygous for the F508del-CFTR mutation. Chest. 2012.

15. Van Goor F., Hadida S., Grootenhuis P. D., Burton B., Stack J. H., Straley K. S., Decker C. J., Miller M., McCartney J. et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc. Natl. Acad. Sci USA. 2011, 108 (46): 18843–18848.

16. Cain C. Cystic fibrosis two-step. SciBX. 2012; 5 (8). Doi:101038/scibx2012192.

17. Study of VX-809 alone and in combination with VX-770 in cystic fibrosis (CF) patients homozygous or heterozygous for the F508del-CFTR mutation. Available at: http://clinicaltrials.gov/ct2/show/NCT01225211?term=ivacaftor&intr=ivacaftor&rank=4

18. Study of VX-661 alone and in combination with VX-770 in subjects homozygous to the F508del-CFTRmutation. Available at:

19. http://clinicaltrials.gov/ct2/show/NCT01531673?term=ivacaftorintr=ivacaftor&rank=2

20. Kerem E., Armoni S., Hirawat S. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008; 372: 719–727.

21. Sermet-Gaudelus I., Boeck K. D., Casimir G. J., Vermeulen F., Leal T., Mogenet A., Roussel D., Fritsch J. et al Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit Care Med. 2010; 182 (10): 1262–1272.

22. Kerem E., Hirawat S., Armoni S., Yaakov Y., Shoseyov D., Cohen M., Nissim-Rafinia M., Blau H., Rivlin J., Aviram M. et al. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet. 2008; 372 (9640): 719–727.

23. Erlinge D. P2Y receptors in health and disease. Adv. Pharmacol. 2011; 61: 417–439.

24. Grasemann H., Stehling F., Brunar H. et al. Inhalation of moli1901 in patients with cystic fibrosis. Chest. 2007; 131: 1461–1466.

25. Accurso F. J., Moss R. B., Wilmott R. W., Anbar R. D., Schaberg A. E., Durham T. A., Ramsey B. W. TIGER-1 Investigator Study Group: Denufosol tetrasodium in patients with cystic fibrosis and normal to mildly impaired lung function. Am. J. Respir. Crit. Care Med. 2011, 183 (5): 627–634.

26. Ratjen F., Durham T., Navratil T., Schaberg A., Accurso F. J., Wainwright C., Barnes M., Moss R. B. the TIGER-2 Study Investigator Group. Long term effects of denufosol tetrasodium in patients with cystic fibrosis. J. Cyst Fibros. 2012; 11 (6): 539–549.

27. Shelepneva N. E., Kashirskaya N. Yu., Sherman V. D. et al. Farmateka – Pharmateca. 2009; 6: 1–4.

28. Kapustina T. Yu. Izmeneniya pecheni i ikh korrektsiya pri mukovistsidoze u detei. Avtoref. diss. … kand. med. nauk [Liver Changes and their Correction in Cystic Fibrosis in Children. Author’s abstract]. Moscow, 2001. 22 p.

29. Simonova O. I., Solov'eva Yu.V., Vasil'eva E. M. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2012; 6: 85–90.

30. Surkov A.N., Gevorkyan A.K., Vashakmadze N.D., Tomilova A.Yu., Simonova O.I. Vozmozhnosti neinvazivnoi diagnostiki stadii fibroza pecheni v pediatrii. Sbornik materialov pervoi Vserossiiskoi nauchnoi konferentsii molodykh uchenykh-medikov «Innovatsionnye tekhnologii v meditsine XXI veka». 6-7 dekabrya [The Possibility of Non-invasive Diagnosis of Liver Fibrosis in Pediatric Patients. The Collection of Materials of the First All-Russian Scientific Conference of Young Scientists, Physicians "Innovative Technologies in Medicine of the XXI Century." December 6-7]. Moscow, 2012. pp. 68-69.

31. Kashirskaya N. Yu. Sostoyanie zheludochno-kishechnogo trakta, podzheludochnoi zhelezy i gepatobiliarnoi sistemy u bol'nykh mukovistsidozom. Avtoref. diss. … dokt. med. nauk [Condition of the Gastrointestinal Tract, Pancreas and Biliary System in Patients with Cystic Fibrosis. Author’s abstract]. Moscow, 2001. 46 p.

32. Dobbin C. J., Bye P. Management of an older patient with S. maltophilia: is it an emerging pathogen in cystic fibrosis? Intern. Med. J. 2001; 31: 499–500.

33. Liu L., Coenye T., Burns J. L. et al. Ribosomal DNA-Directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J. Clinical Microbiology. 2002; 40 (4): 1210–1213.

34. Amoureux L., Bador J., Siebor E., Taillefumier N. et al. Epidemiology and resistance of Achromobacter xylosoxidans from cystic fibrosis patients in Dijon, Burgundy: First French data. J. Cystic Fibrosis. 2012; 11 (4): 305–311.

35. Mantovani R. P., Levy C. E., Esteves C. Z., Ribeiro J. D., Ribeiro A. F., Bernardi D. M., Yano T. Virulence properties of Achromo bacter xylosoxidans: cytotoxic activity, interleukin production, biofilm formation and invasion. J. Cystic Fibrosis. 2010 Jun; 9 (Suppl. 1): S35.

36. Asherova I. K., Feizhel'son Zh., Amelina E. L., Kashirskaya N. Yu., Kapranov N. I. Pul'monologiya = Pulmonology. 2012; 4: 34–39.

37. Colombo C., Crosignani A., Battezzati M. Liver involvement in cystic fibrosis. J. Hepatol. 1999; 31: 946–954.

38. Strandvik B. Hepatobiliary disease in Cystic fibrosis. Diseases of the liver and biliary system children (ed. D. A. Kelly). Blackwell Science Ltd., London. UK. 1999. pp. 141–156.

39. Castellani C., Cuppens H., Macek M.Jr., Cassiman J. J., Kerem E., Durie et al. The use and interpretation of cystic fibrosis mutation analysis in clinical practice. Evropeiskii konsensus = European consensus.2009; 1–28.

40. Kerem E. Mutation specific therapy in CF. Paediatr. Respir. Rev. 2006; 7 (1): 166–169.